Clinical trials: Hepatitis C Virus (HCV)
Chronic Hepatitis C(CHC)
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.
- Trial name
- NCT01753570
- Testing
- MP-424, RBV(24 weeks), IFN beta(24 weeks)
- Where
- Japan
- Volunteers
- 74 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C
Advanced Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants
The overarching goal of this study is to develop a peer-based care coordination intervention for individuals with Hepatitis C Virus (HCV) who were recently released from correctional settings to promote linkage to and retention…
- Trial name
- ACCELERATE (NCT04701437)
- Testing
- Peer mentor, Standard of care
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Montefiore Medical Center
Hepatitis C, Hiv
Universal HIV Screening and Targeted HCV Screening in Emergency Department
Cross-sectional study of patients consulting in the emergency room of the Centre hospitalier de l'Université de Montréal (CHUM), to assess the implementation of an "opt-out" screening program for HIV and HCV and prospective…
- Trial name
- NCT03595527
- Testing
- HIV and HCV screening
- Where
- Canada
- Volunteers
- 6,350 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Hepatitis C Recurrence
A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation
Recurrence of Hepatitis C virus infection (HCV) is universal after orthotopic liver transplantation (LTx) and is associated with allograft failure, death and need for re-transplantation.
- Trial name
- NCT01074203
- Testing
- Nitazoxanide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Chronic Hepatitis C
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)
This is a 2-part study. The purpose of Part A is to assess the efficacy and safety of grazoprevir (MK-5172) 100 mg in combination with elbasvir (MK-8742) 50 mg for 12 weeks in the treatment of chronic HCV GT1, GT4, or GT6…
- Trial name
- C-EDGE CO-STAR (NCT02105688)
- Testing
- Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
- Volunteers
- 301 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus
HCV Care Pathway in Ile-de-France
The main objective of this research is to evaluate a care pathway adapted to different category populations at risk of being infected with the hepatitis C virus in order to improve both the diagnosis turnaround times and the…
- Trial name
- ParcoursVHC (NCT02893046)
- Testing
- No intervention
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV, Hepatitis C
A Methadone Maintenance Treatment Outcome Study in Three Provinces in China
The primary goal of this PHE is to determine the effectiveness of a tailored education program for MMT service providers. It was to be evaluated through methadone dose levels prescribed to new patients after training completion.
- Conditions
- HIV, Hepatitis C, Syphilis, Herpes Simplex Type II
- Trial name
- NCT01315054
- Testing
- MMT provider dosage training, targeted counseling, national guidelines
- Where
- China
- Volunteers
- 4,258 people
- Sponsor
- Centers for Disease Control and Prevention
Hepatitis C
Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
This is a multi-site, open-label trial evaluating the safety and efficacy of 100 mg of grazoprevir (MK-5172) used in combination with or without 50 mg of elbasvir (MK-8742) and/or ribavirin (RBV) in treating non-cirrhotic…
- Trial name
- NCT01932762
- Testing
- Grazoprevir, Elbasvir, Ribavirin
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection
This study is to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with nosocomial genotype 1 hepatitis C virus (HCV) infection.
- Trial name
- NCT01924949
- Testing
- LDV/SOF
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Gilead Sciences
HIV Coinfection
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.
- Trial name
- NCT01327547
- Testing
- Maraviroc
- Where
- 48 sites in United States, Czechia and 7 more
- Volunteers
- 138 people
- Sponsor
- ViiV Healthcare
Chronic Hepatitis C
A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3
A Study of Albuferon with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 2 or 3.
- Trial name
- NCT00656006
- Testing
- Albuferon, Ribavirin
- Where
- 6 sites in Canada
- Volunteers
- 43 people
- Sponsor
- Human Genome Sciences Inc.
Hepatitis C, Chronic
Gilead Sustained Virologic Response (SVR) Registry
This Registry is designed to provide long term clinical and virologic follow up in participants who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored hepatitis C virus (HCV)…
- Trial name
- NCT01457755
- Where
- 325 sites in United States, Australia and 15 more
- Volunteers
- 6,625 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection
This clinical study will evaluate whether grazoprevir and elbasvir is efficacious, safe, and well-tolerated in peginterferon alfa plus ribavirin experienced patients who inject drugs (PWID) and men who sex with men (MSM) with…
- Trial name
- NCT03098121
- Testing
- grazoprevir and elbasvir
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Taoyuan General Hospital
HCV Infection ( Genotype 4) in CKD Patients
Treatment of CKD Patients With HCV
The goal of this clinical trial is to evaluate the optimal drug therapy of HCV in CKD Patients different stages with or without compensated cirrhosis.
- Trial name
- HCV/CKD (NCT07770984)
- Testing
- SOF+DCV, OBV/PTV/r) ± ribavirin (RBV)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Hepatic Insufficiency
Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment
The primary objectives were: To determine the effects of steady state TPV co-administered with low dose RTV on steady state PegIFN and RBV in HIV negative subjects with mild hepatic impairment (scheme A) To determine the effects…
- Trial name
- NCT02259855
- Testing
- Tipranavir, Ritonavir, Pegylated interferon
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatitis C, Alcohol Use Disorders
Baclofen to Reduce Alcohol Use in Veterans With HCV
Hepatitis C (HCV) is the most common blood born virus in the United States, affecting 1.8% of the general population and more than 5% of Veterans using VA facilities.
- Trial name
- BRAC (NCT01008280)
- Testing
- baclofen
- Where
- 4 sites in United States
- Volunteers
- 180 people
- Sponsor
- VA Office of Research and Development
Hepatitis C
Ask a Friend to Take a Test for Hepatitis C Infection
This exploratory study will carry out a respondent-driven sampling exercise, where participants will identify their previous injecting partners and contact these individuals to invite them to take an Hepatitis C test.
- Trial name
- NCT03697135
- Testing
- Respondent Driven Sampling
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- NHS Tayside
Hepatitis C Virus Infection
Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4
The objective of the investigators was to delineate the efficacy and safety of Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) plus ribavirin (RBV) on chronic HCV GT4 Egyptian naïve patients
- Trial name
- NCT04378608
- Testing
- OBV/PTV/r) ± ribavirin (RBV)
- Volunteers
- 100 people
- Sponsor
- Beni-Suef University
Hepatitis C
A Self-efficAcy Intervention to reDuce Injecting Risk behAviour and hePatitis c reinfecTion Rates
The study evaluates the use of implementation intentions to increase self-efficacy and reduce injecting risk behaviour in a sample of injecting drug users on treatment for hepatitis C (HCV).
- Trial name
- ADAPT (NCT03293576)
- Testing
- Volitional Help Sheet
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- University of Dundee
Hepatitis C
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.
- Trial name
- NCT00097435
- Testing
- Albuferon, Ribavirin
- Where
- 8 sites in United States
- Volunteers
- 115 people
- Sponsor
- Human Genome Sciences Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.